Our results are similar to those of a study performed by Maisonneuve et al. [45], in which the distributions of luminal A and luminal B HER2-negative cases among 9,415 patients who underwent surgery for endocrine-responsive HER2-negative breast cancer, were investigated. This evidence concerns the gene ERBB2 and breast carcinoma.